title: Cyclophosphamide-induced generalised reticulated skin pigmentation: a rare presentation.
abstract: METHODS
  We describe a 55-year-old woman suffering from Sezary syndrome, had undergone chemotherapy consisting of cycles of cyclophosphamide and prednisone. 10 months later, she noticed a progressively increasing reticulated generalised pigmentation in the face, trunk and the extremities. Cylophosphamide was withdrawn. The hyperpigmentation began to clear slowly and gradually after 7 months. One year after cyclophosphamide withdrawal and facing the relapse of the disease, and its transformation to a large T cell lymphoma a mini CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) protocol was held, leading to a remarkable aggravation of the pigmentation.
  
  
  CONCLUSIONS
  This adverse drug reaction to cyclophosphamide is peculiar by its localization and distribution and should be known in order not to confuse with other dermatosis.
authors.affiliation: Dermatology Department, Fattouma Bourguiba Hospital, 5000 Monastir, Tunisia. monia.youssef@gmail.com
authors.forename: Monia
authors.initials: M
authors.lastname: Youssef
authors.forename: Sana
authors.initials: S
authors.lastname: Mokni
authors.forename: Hichem
authors.initials: H
authors.lastname: Belhadjali
authors.forename: Karim
authors.initials: K
authors.lastname: Aouem
authors.forename: Adnène
authors.initials: A
authors.lastname: Moussa
authors.forename: Adnène
authors.initials: A
authors.lastname: Laatiri
authors.forename: Jameleddine
authors.initials: J
authors.lastname: Zili
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced*; D008875:Middle Aged; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D012751:Sezary Syndrome / Q000188:drug therapy; D012878:Skin Neoplasms / Q000188:drug therapy; D012880:Skin Pigmentation / Q000187:drug effects*; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone